Bibliography
  1. Guyatt G, Rennie D, Meade MO, Cook, D. Users’ Guides to the Medical Literature: A Manual for Evidence-Based Clinical Practice. Chapter 1. Third Edition. 2015.
  2. Rothwell PM. Treating individuals 2. Subgroup analysis in randomised controlled trials: importance, indications, and interpretation. Lancet 2005; 365 (9454): 176-86.
  3. VanderWeele TJ, Knol MJ. Interpretation of subgroup analyses in randomized trials: heterogeneity versus secondary interventions. Ann Intern Med 2011;154:680e3.
  4. Sun X, Ioannidis JP, Agoritsas T, Alba AC, Guyatt G.. How to use a subgroup analysis: users’ guide to the medical literature. JAMA 2014;311:405e11.
  5. Thanarajasingam G, Minasian LM, Baron F, et al. Beyond maximum grade: modernising the assessment and reporting of adverse events in haematological malignancies [published correction appears in Lancet Haematol. 2019 Mar;6(3):e121]. Lancet Haematol. 2018;5(11):e563‐e598.
  6. Bennett CL, Tigue CC, Angelotta C, McKoy JM, Edwards BJ Adverse effects of drugs used to treat hematologic malignancies: surveillance efforts from the research on adverse drug events and reports project. Semin Thromb Hemost. 2007;33(4):365‐372.
  7. Wittes J. On looking at subgroups. Circulation . 2009;119(7):912‐915.
  8. Wang R, Lagakos SW, Ware JH, Hunter DJ, Drazen JM. Statistics in medicine—reporting of subgroup analyses in clinical trials. N Engl J Med . 2007;357(21):2189‐2194.
  9. Koch A, Framke T. Reliably basing conclusions on subgroups of randomized clinical trials. J Biopharm Stat . 2014;24(1):42‐57.
  10. Vidic A, Chibnall JT, Goparaju N, et al. Subgroup analyses of randomized clinical trials in heart failure: facts and numbers. ESC Heart Fail. 2016 Sep; 3(3): 152–157.
  11. Wijn SRW, Rovers MM, Le LH, et al. Guidance from key organisations on exploring, confirming and interpreting subgroup effects of medical treatments: a scoping review. BMJ Open. 2019;9(8):e028751.
  12. Gil-Sierra MD, Fénix-Caballero S, Abdel-Kader Martin L, et al. Checklist for Clinical Applicability of Subgroup Analysis. J Clin Pharm Ther. 2020 Jun;45(3):530-538
  13. Oxman AD, Guyatt GH. A consumer’s guide to subgroup analyses. Ann Intern Med 1992;116:78-84.
  14. Sun X, Briel M, Walter SD, et al. Is a subgroup effect believable? Updating criteria to evaluate the credibility of subgroup analyses. BMJ 2010;340:c117.
  15. Sun X, Ioannidis JPA, Agoritsas T, et al. How to use a subgroup analysis. JAMA 2014;311:405
  16. Sun X, Briel M, Busse JW, et al. Subgroup Analysis of Trials Is Rarely Easy (SATIRE): a study protocol for a systematic review to characterize the analysis, reporting, and claim of subgroup effects in randomized trials. Trials. 2009;10:101.
  17. Sun X, Briel M, Busse JW, et al. Credibility of claims of subgroup effects in randomised controlled trials: systematic review. BMJ. 2012;344:e1553.
  18. Moher D., Liberati A., Tetzlaff J, et al. Group P. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. Int. J. Surg. 2010;8:336–341.
  19. Oxman AD. Subgroup analyses. BMJ 2012;344:e2022.
  20. Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.0 (updated July 2019). Cochrane, 2019. Available from www.training.cochrane.org/handbook.
  21. Primo J, Escrig J. MetaSurv: Excel calculator for survival meta-analyzes. 2008. Avaialble in: http://www.redcaspe.org/herramientas/descargas/MetaSurv.xls
  22. Brookes ST, Whitely E, Egger M, Smith GD, Mulheran PA, Peters TJ. Subgroup analyses in randomized trials: risks of subgroup-specific analyses; power and sample size for the interaction test. J Clin Epidemiol 2004; 57: 229–236.
  23. Assmann SF, Pocock SJ, Enos LE, Kasten LE.. Subgroup analysis and other (mis) uses of baseline data in clinical trials. Lancet 2000; 355: 1064–1069.
  24. Feinstein AR. The problem of cogent subgroups: a clinicostatistical tragedy. J Clin Epidemiol 1998; 51: 297–299.
  25. Moreira ED Jr, Stein Z, Susser E. Reporting on methods of subgroup analysis in clinical trials: a survey of four scientific journals. Braz J Med Biol Res. 2001;34(11):1441‐1446.
  26. Zhang S, Liang F, Li W, Hu X. Subgroup Analyses in Reporting of Phase III Clinical Trials in Solid Tumors. J Clin Oncol . 2015;33(15):1697‐1702.
  27. Schulz KF, Altman DG, Moher D; CONSORT Group. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. Int J Surg. 2011;9(8):672‐677.
  28. Mistry D, Patel S, Hee SW, Stallard N, Underwood M. Evaluating the quality of subgroup analyses in randomized controlled trials of therapist-delivered interventions for nonspecific low back pain: a systematic review. Spine (Phila Pa 1976) 2014;39:618e29.
  29. Saragiotto BT, Maher CG, Moseley AM, et al. A systematic review reveals that the credibility of subgroup claims in low back pain trials was low. J Clin Epidemiol. 2016;79:3‐9.